Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
about
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in SwitzerlandMultilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.What does PD-L1 positive or negative mean?Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.The importance for immunoregulation for long-term cancer control.Immunogenomics: using genomics to personalize cancer immunotherapy.Targeted agents and immunotherapies: optimizing outcomes in melanoma.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Mechanisms of Drug Resistance in Melanoma.Molecular genetic and immunotherapeutic targets in metastatic melanoma.Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.The immune contexture in cancer prognosis and treatment.PD1 signal transduction pathways in T cells.Immunotherapy resistance: the answers lie ahead - not in front - of us.Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances.Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous MelanomaGenetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer.Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma.DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade.Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.Intratumoral immunotherapy: using the tumor as the remedy.Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.Implications of the tumor immune microenvironment for staging and therapeutics.Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.The diverse functions of the PD1 inhibitory pathway.Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
P2860
Q30491702-18D4E008-893F-418F-AFBD-7793EB864EBEQ33722799-C7EFAAC4-2C07-46CF-8945-129951887119Q33766695-955A3204-E17B-43A5-AA7F-5592148050DBQ33832752-06B34321-C10B-4AC7-A613-44346C34571DQ33839204-E30A94CD-ECC8-427A-BA8E-702E938AC6A7Q37500381-8B43BCF4-3640-4EF6-BEDE-17277D4B805EQ37739214-63E17D7C-0356-4E49-9A60-08E3C560BCC9Q38401891-4CF533CF-1B9C-4D8C-AAB1-C8AFB8C6FAD2Q38647002-522EA291-D282-441F-BC0F-70609A5C3BD8Q38772744-BCD930C3-6DC5-4530-AA7C-0079594AC0EAQ38856722-D605C1C8-7D66-4045-BC5E-F83C9FF750FEQ39130451-21F02001-1D43-40C2-B727-6FF613756F0EQ39169776-572FFE55-8329-4946-A325-5C2A519A171AQ39208242-F02C6C70-8D08-4222-8AAC-4A86B955ED74Q39312652-4C9986E6-2CB9-4C83-A2B3-9B2EB24A40ECQ39456999-0881AEC5-D409-4853-BC6B-8EB0CE3F545BQ40062424-209A644F-49D7-4073-BEEB-94C98449A608Q42320552-A7E8FA53-15A0-4152-B6DC-19B0419610D5Q42353279-69C7407F-06C2-4F6B-AC23-EF2398AA00C2Q42362520-9115FAC5-03F5-42C1-B9A6-CBC8834BA2ECQ42365255-B779083D-548D-450D-A81C-9CE544CAEB97Q42378297-74B488AF-2DA1-4CB4-A71F-8FA581DF6488Q42700740-BD3A12CF-A9DB-417E-8F32-067CBDC0B999Q45968787-C80FE961-6978-4DF4-837A-43E47063D36BQ46096916-74C89DCA-89C2-4517-884C-8F7E0AE02EF1Q47098333-A0DD7827-C92A-4BD1-9E6F-D6AAF979BFAFQ47113049-4BA013FB-3195-4A59-BF4A-3BA7E8985920Q47113174-83F8C9B0-84C1-4A86-BC9F-51A14AC1FBA4Q47120629-32F638CA-F4FF-43FD-AF32-56CA2D742D2FQ47135020-E11AB087-342A-4FF5-A947-1A842CF1C1D0Q47151526-A6A098B3-892E-4F19-A912-9E0C615DEE2AQ47219905-7C930A31-3FCD-4CC9-8527-4CB7880BE0DAQ47281370-D4239917-DE16-4032-8FAB-6CC624875CBFQ47292249-C09025A9-6B63-4B69-AFBE-801B98136AE5Q47329066-9B1E674A-B716-447A-8194-04CE455D8817Q47592007-B11D8639-B0E9-404A-8673-5F41C84F25F6Q47652834-B084EA8B-1DB1-4AED-99FE-7A49723D0CA9Q47678849-AC66B3D6-EB1B-4EA7-8965-93F15C0CE6BDQ47701712-A81FF8BD-24F5-471F-BC7E-22C2736E2FC4Q47794460-B22E105B-3230-46DF-AE37-6C1C6A7BF762
P2860
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
@en
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
@nl
type
label
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
@en
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
@nl
prefLabel
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
@en
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
@nl
P2093
P2860
P50
P1433
P1476
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
@en
P2093
Angel Garcia-Diaz
Ariel Azhdam
Beata Berent-Maoz
Catherine S Grasso
Davis Y Torrejon
Drew M Pardoll
Elizabeth Seja
Gabriel Abril Rodriguez
Giulia Parisi
P2860
P304
P356
10.1158/2159-8290.CD-16-1223
P50
P577
2016-11-30T00:00:00Z